Conclusions: Timely adjustment of IFX dose/dosing interval can be facilitated by IFX concentration measurement in home-sampled DBS. DBS is a reliable method to measure IFX and can be used to predict IFX trough concentrations. KEYWORDS biologicals, clinical pharmacology, gastroenterology, immunology, therapeutic drug monitoring
| INTRODUCTION
Therapeutic drug monitoring (TDM) can form an important tool to optimize efficacy of infliximab (IFX) treatment in patients with inflammatory bowel disease (IBD).
1-3 TDM for IFX in IBD patients is currently only applied in a reactive manner. Clinicians request a serum IFX concentration measurement when a patient does not respond to therapy (primary non-responders) or loses response while on treatment (secondary non-responders). Proactively maintaining trough concentrations above a target threshold, assures optimal treatment and can prevent deleterious anti-drug antibody formation. [4] [5] [6] [7] [8] As venous blood samples are drawn when the patient presents at the clinic and samples are sent off for measurements, there is a delay between the collection of the serum sample and the availability of the results. As a consequence, dose adjustment usually can only be carried out at the following IFX infusion 8 weeks later, a delay that may significantly reduce the utility of TDM. 7 Dried blood samples (DBS) with capillary blood obtained via a finger prick could greatly facilitate TDM, because patients can perform this finger prick anywhere and at any time prior to the next infusion. In this case, results of the measurements of DBS will be present when the patient visits the clinic and the dose can be adjusted immediately. At the same time, this alleviates the stress induced by venous blood collection. 9 Therapeutic monoclonal antibodies and anti-drug antibodies can be accurately quantified in capillary blood samples. 10 This is supported by further anti-tumor necrosis factor (TNF) measurements in capillary blood samples in patients with inflammatory disease treated with adalimumab. 11, 12 For these studies, Whatman® paper has been used to collect capillary blood. Because the handling of DBS on Whatman® paper is laborious, new methods for capillary blood sampling have entered the market.
The Mitra™ microsampler, a novel device to collect capillary blood, also gives reliable results and, moreover, improves efficacy of sampling handling. 13 The purpose of this study is to validate the clinical application of DBS for IFX in IBD patients using the Mitra™ microsampler. Capillary blood sampling consists of whole blood. To express the drug levels as weight per volume serum, volume whole blood needs to be converted to volume serum. Therefore, haematocrit (Hct) values are needed to convert DBS results into comparable serum IFX concentration. Here, different approaches of Hct estimations were evaluated. Additionally, in this study, the feasibility of using DBS to estimate serum IFX concentrations by patients at home was evaluated. (Amsterdam, The Netherlands). Before performing the finger prick at home, patients were instructed by a trained healthcare professional how to use the device. Also, a leaflet was provided with detailed instructions on how to perform a finger prick at home which was guided by text and pictures. The study was approved by the local ethical committee and all patients gave written informed consent before enrolment.
| Infliximab and antibodies-to-infliximab measurements
All IFX concentrations were measured by an enzyme-linked immunosorbent assay (ELISA), as described in a previous study. 14 2 What is already known about this subject
• Infliximab serum concentrations are associated with improved treatment outcomes in IBD patients.
• The use of capillary blood on Whatman® paper has been clinically validated for the measurement of therapeutic monoclonal antibody adalimumab.
What this study adds
• Infliximab can be accurately measured in capillary blood using Mitra™ tips in IBD patients.
• Dried blood sampling, with a finger prick, can be performed by the patient at home.
HPE) was added for 1 hour at 37°C. After washing, the ELISA was developed with 100 mg L −1 tetramethylbenzidine in 0. 
| Elution of capillary blood from DBS
The finger prick was performed using a contact-activated lancet (BD Microtainer® 2.0 mm × 1.5 mm). Capillary blood was collected via a Mitra™ microsampling device with volumetric absorptive microsampler (VAMS) technology. 15 The microsampling device consists of an absorbent polymeric tip designed to take up a fixed volume of blood by capillary action. This device overcomes some of the technical issues associated with blood volume variability and Hct that are reported when taking a punch from dried blood spots on Whatman® paper. 16 The Mitra™ tips filled with blood were removed from the holder and eluted in elution buffer (PBS/0.05%Tween/0.05% NaN 3 ) vigorously shaking overnight (≥17 hours) on an orbital shaker. After removal, the eluate was kept at 4°C until measurements were performed. 13 ). An overview of all methods is provided in Table S1 . Hct was measured in whole blood with the XN9000 from Sysmex (Amsterdam UMC, The Netherlands) with linearity between 0 and 0.75 L L −1 .
| Haematocrit (Hct) for conversion of DBS results

| Bayesian pharmacokinetic analysis
One week before visiting the infusion unit, at time point 4, patients performed a finger prick at home without matching venepuncture. Twelve patients were lost to follow-up resulting in 28 samples from time point 3. In total, 106 IFX matching venepuncture/DBS samples were collected. Twenty-eight additional DBS samples, performed by the patient at home, were collected.
| Infliximab measurements in DBS
The IFX serum concentrations collected at time point 1 (trough), time Disease duration, years 13 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Albumin, g L ). The corresponding serum sample of this patient had IFX serum trough concentrations below LLOQ and also a high level of ATI (>880 AU ml −1 ).
| DISCUSSION
This study shows that DBS via finger prick is a reliable method to measure IFX concentrations in IBD patients. Results for measured IFX serum concentrations using DBS are highly comparable to measured IFX serum concentrations after conventional venepuncture. Most importantly, we are the first to show that sampling at home leads to accurate IFX concentration results which will optimize the use of TDM in IBD patients treated with the anti-TNF monoclonal IFX.
The use of capillary blood for measuring drug concentrations finds application in various fields. So far, the use of capillary blood has been described mainly for bioanalysis of small molecules. 23 Therapeutic and toxic drug concentrations can be measured in capillary blood for antibiotics, anti-epileptics, anti-HIV agents, immune-suppressants and in the cardiovascular field, among others. 24 The use of capillary blood in (young) children also is of great interest, because blood collection from children is always challenged by ethical issues. Besides the ease of blood collection, using capillary blood can be cost-saving as it reduce the need for visits to the (outpatient) clinic. 25 This current study is a prospective observational study of IBD patients treated with IFX. We show here that the Mitra™ tip is a reliable tool to measure IFX concentrations in IBD patients.
To the best of our knowledge, we are also the first to show that This way, using DBS will greatly facilitate both proactive and reactive TDM of IFX.
Our study has several limitations. First, our validation of home sampling is limited by the number of samples collected (n = 28). 
